Jeff Yass’s UroGen Pharma URGN Stock Holding History

Jeff Yass’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.53M	Buy	150,300 +32,300	+27%	+$875K	﹤0.01%	4420
2026 Q1	$2.12M	Sell	118,000 -48,900	-29%	-$980K	﹤0.01%	6045
2025 Q4	$3.91M	Sell	166,900 -202,800	-55%	-$4.4M	﹤0.01%	4432
2025 Q3	$7.38M	Sell	369,700 -116,600	-24%	-$2.09M	﹤0.01%	3470
2025 Q2	$6.66M	Buy	486,300 +466,100	+2,307%	+$4.47M	﹤0.01%	3473
2025 Q1	$223K	Buy	+20,200	New	+$215K	﹤0.01%	10716
2024 Q4	–	Sell	-12,200	Closed	-$155K	–	13287
2024 Q3	$155K	Sell	12,200 -47,300	-79%	-$702K	﹤0.01%	10712
2024 Q2	$998K	Buy	59,500 +35,000	+143%	+$498K	﹤0.01%	6599
2024 Q1	$368K	Buy	+24,500	New	+$400K	﹤0.01%	9236
2023 Q4	–	Sell	-13,900	Closed	-$195K	–	13346
2023 Q3	$195K	Buy	+13,900	New	+$223K	﹤0.01%	10259
2023 Q2	–	Sell	-35,500	Closed	-$328K	–	13184
2023 Q1	$328K	Sell	35,500 -7,400	-17%	-$68.1K	﹤0.01%	9515
2022 Q4	$381K	Buy	42,900 +21,400	+100%	+$203K	﹤0.01%	8518
2022 Q3	$179K	Buy	+21,500	New	+$178K	﹤0.01%	10997
2020 Q4	–	Sell	-25,500	Closed	-$492K	–	11766
2020 Q3	$492K	Sell	25,500 -11,900	-32%	-$269K	﹤0.01%	7713
2020 Q2	$977K	Sell	37,400 -87,100	-70%	-$2.13M	﹤0.01%	5984
2020 Q1	$2.22M	Buy	124,500 +25,000	+25%	+$675K	﹤0.01%	3792
2019 Q4	$3.32M	Buy	99,500 +49,900	+101%	+$1.36M	﹤0.01%	3537
2019 Q3	$1.18M	Buy	49,600 +9,500	+24%	+$311K	﹤0.01%	5328
2019 Q2	$1.44M	Buy	40,100 +2,700	+7%	+$99.5K	﹤0.01%	4869
2019 Q1	$1.38M	Buy	37,400 +29,400	+368%	+$1.23M	﹤0.01%	4372
2018 Q4	$344K	Buy	+8,000	New	+$360K	﹤0.01%	6752

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jeff Yass's URGN Position: Q2 2026 in Review

Jeff Yass reduced its UroGen Pharma (URGN) stake by 92% in Q2 2026, selling an estimated $2.08M and leaving 6,782 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #11467.

Jeff Yass first reported a position in URGN in Q3 2018 and has held it in 24 quarters since. The position peaked at $6.64M in Q2 2025. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Jeff Yass held 6,782 shares of UroGen Pharma worth $250K as of Q2 2026.
Jeff Yass sold 76,841 UroGen Pharma shares in Q2 2026, an estimated $2.08M.
UroGen Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11467 holding.
Jeff Yass first reported a position in UroGen Pharma in Q3 2018 and has held it in 24 quarters since.
Jeff Yass's UroGen Pharma position peaked at $6.64M in Q2 2025.
188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.